Driehaus Capital Management LLC Acquires 1,130 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Driehaus Capital Management LLC lifted its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 3.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 33,480 shares of the biopharmaceutical company's stock after acquiring an additional 1,130 shares during the period. Driehaus Capital Management LLC's holdings in Alnylam Pharmaceuticals were worth $7,878,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently made changes to their positions in the stock. Jennison Associates LLC acquired a new stake in Alnylam Pharmaceuticals during the fourth quarter valued at approximately $61,160,000. Strategic Financial Concepts LLC acquired a new position in Alnylam Pharmaceuticals in the 4th quarter worth approximately $41,529,000. Truist Financial Corp grew its position in Alnylam Pharmaceuticals by 136.6% during the 4th quarter. Truist Financial Corp now owns 4,398 shares of the biopharmaceutical company's stock worth $1,035,000 after purchasing an additional 2,539 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. grew its position in Alnylam Pharmaceuticals by 3.0% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 286,703 shares of the biopharmaceutical company's stock worth $67,464,000 after purchasing an additional 8,462 shares in the last quarter. Finally, Assenagon Asset Management S.A. grew its position in Alnylam Pharmaceuticals by 13.0% during the 4th quarter. Assenagon Asset Management S.A. now owns 19,918 shares of the biopharmaceutical company's stock worth $4,687,000 after purchasing an additional 2,285 shares in the last quarter. 92.97% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have weighed in on the stock. Wells Fargo & Company lifted their price objective on shares of Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the stock an "equal weight" rating in a research report on Friday, March 21st. StockNews.com upgraded shares of Alnylam Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. Canaccord Genuity Group raised their price target on shares of Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the company a "buy" rating in a report on Friday, March 21st. Chardan Capital raised their target price on shares of Alnylam Pharmaceuticals from $300.00 to $325.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. Finally, William Blair reiterated an "outperform" rating on shares of Alnylam Pharmaceuticals in a research note on Friday, March 21st. One analyst has rated the stock with a sell rating, four have assigned a hold rating and twenty-two have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $319.17.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 663 shares of the business's stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $255.21, for a total transaction of $169,204.23. Following the completion of the sale, the executive vice president now directly owns 14,321 shares in the company, valued at $3,654,862.41. The trade was a 4.42% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Jeffrey V. Poulton sold 967 shares of the business's stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $255.17, for a total value of $246,749.39. Following the sale, the chief financial officer now owns 32,786 shares of the company's stock, valued at approximately $8,366,003.62. This represents a 2.86% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 7,392 shares of company stock valued at $1,875,627 over the last quarter. 1.50% of the stock is owned by company insiders.

Alnylam Pharmaceuticals Trading Up 6.1%

Shares of NASDAQ:ALNY traded up $16.37 during trading on Thursday, reaching $283.92. 636,817 shares of the company traded hands, compared to its average volume of 905,398. The firm has a market capitalization of $37.02 billion, a price-to-earnings ratio of -130.81 and a beta of 0.17. Alnylam Pharmaceuticals, Inc. has a 52-week low of $144.73 and a 52-week high of $304.39. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. The business's fifty day moving average is $251.79 and its 200-day moving average is $253.79.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.07). The company had revenue of $594.19 million during the quarter, compared to the consensus estimate of $584.32 million. During the same period last year, the firm earned ($0.16) earnings per share. The firm's revenue for the quarter was up 20.2% compared to the same quarter last year. As a group, analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.